Acurex Biosciences Receives U.S. Patent for CU-00048
The patent protects CU-00048 into 2042. The company describes the drug candidate as a potential T-type calcium channel antagonist for essential tremor.
The patent protects CU-00048 into 2042. The company describes the drug candidate as a potential T-type calcium channel antagonist for essential tremor.